Jin Su-Eon, Jin Hyo-Eon, Hong Soon-Sun
a 1 Yonsei University, College of Pharmacy , Incheon, 406-840, Republic of Korea.
b 2 University of California, Lawrence Berkeley National Laboratory, Department of Bioengineering, Berkeley and Physical Biosciences Division , Berkeley, CA 94720, USA.
Expert Opin Ther Targets. 2015;19(10):1319-37. doi: 10.1517/14728222.2015.1044975. Epub 2015 May 12.
L-type amino acid transporter 1 (LAT1) is one of the amino acid transporters. It is overexpressed in various types of cancer cells, while it is produced restrictedly in normal tissues.
We discuss its characteristics in cancer cells compared with normal cells. We also mention the current applications to target LAT1 for anticancer therapy focusing on prognostic biomarkers, radio-labeled tumor imaging reagents, amino acid-stapled prodrugs, LAT1-mediated enhanced transport of anticancer drugs and LAT1 inhibitors.
LAT1 can be a versatile target to promisingly develop transporter-based drugs with enhanced drug delivery potential for anticancer therapy.
L型氨基酸转运体1（LAT1）是氨基酸转运体之一。它在各种类型的癌细胞中过度表达，而在正常组织中表达受限。
我们讨论了它在癌细胞与正常细胞中的特征。我们还提及了目前针对LAT1用于抗癌治疗的应用，重点关注预后生物标志物、放射性标记的肿瘤成像试剂、氨基酸稳定化前药、LAT1介导的抗癌药物增强转运以及LAT1抑制剂。
LAT1可以成为一个通用靶点，有望开发出具有增强药物递送潜力的基于转运体的抗癌治疗药物。
